

Special Issue on **Purinergic Receptors in Inflammation: Physiology, Pathology, and Drug Development**

CALL FOR PAPERS

Adenosine and adenosine triphosphate (ATP) are ancestral molecules regulating a diversity of biological processes through activation of P1 (G-protein-coupled A₁, A_{2A}, A_{2B}, and A₃) and P2 (ionotropic P2X and metabotropic P2Y) purinoceptors, respectively. Stimulation of purinoceptors is modulated by the activity of membrane-bound ectoenzymes that metabolize their ligands.

ATP is a proinflammatory “danger signal” released from damaged cells promoting activation of a variety of immune cells and that, under pathophysiological conditions, is metabolized ultimately to the anti-inflammatory mediator adenosine. There is a growing body of evidence that alteration in purinergic system signaling is involved in neurodegenerative, autoimmune, and inflammatory pathologies such as multiple sclerosis, Parkinson’s and Alzheimer’s diseases, ischemia, pain, asthma, COPD, rheumatoid arthritis, osteoarthritis, psoriasis, wound healing, inflammatory bowel disease, eye diseases, cancer, cardiovascular diseases, and transplant rejection, making purinergic ligands valuable potential drug targets.

We invite authors to contribute original research and review articles that will help to understand the role of purinergic receptors in inflammation. We encourage submission of manuscripts describing novel ligands towards the purinergic system and those reporting original studies at molecular, cellular, and tissue levels, including in vitro/animal/human studies.

Potential topics include but are not limited to the following:

- ▶ Medicinal chemistry of novel ligands/compounds/antibodies targeting purinergic system
- ▶ Effects of purinergic drugs in the “purinome” cascade to fine-tuning that regulate the activity of immune/inflammatory cells
- ▶ Purinergic receptors as drug targets of neurodegenerative/autoimmune/inflammatory pathologies

Authors can submit their manuscripts through the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/mi/prip/>.

Lead Guest Editor

Stefania Gessi, University of Ferrara,
Ferrara, Italy
gss@unife.it

Guest Editors

Ken A. Jacobson, National Institutes of
Health, Bethesda, USA
kennethj@helix.nih.gov

Pnina Fishman, Can-Fite BioPharma
Ltd., Kiryat Matalon, Israel
pnina@canfite.co.il

Pier G. Baraldi, Università di Ferrara,
Ferrara, Italy
baraldi@unife.it

Manuscript Due

Friday, 25 November 2016

First Round of Reviews

Friday, 17 February 2017

Publication Date

Friday, 14 April 2017